1. Volume 138, Issue 1, Pages 123-135.e2 (January 2010)
Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection 
Gregory J. Dore, Margaret Hellard, Gail V. Matthews, Jason Grebely, Paul S. Haber, Kathy Petoumenos, Barbara Yeung, Philippa Marks, Ingrid van Beek, Geoffrey McCaughan, Peter White, Rosemary French, William Rawlinson, Andrew R. Lloyd, John M. Kaldor 
Gastroenterology 
Volume 138, Issue 1, Pages e2 (January 2010)
DOI: /j.gastro
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Overview of study population. At least 1 dose of PEG-IFN was administered to 111 participants. Two HCV/HIV coinfected participants received PEG-IFN monotherapy (both nonresponders) before a protocol amendment in which HCV/HIV participants then received PEG-IFN and ribavirin combination therapy.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2 Overview of HCV mono-infected participant population.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
Response rates in (A) HCV mono-infected participants and (B) HCV/HIV co-infected participants in the total study population (intent-to-treat) and per-protocol population.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

5. Figure 4
Time to HCV-RNA clearance among treated and untreated participants in the ATAHC study.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Adherence to PEG-IFN by the number of total PEG-IFN alfa-2a injections received in HCV (n = 74) and HCV/HIV infected (n = 35) participants.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

7. Supplementary Figure 2
Impact of baseline HCV-RNA level on SVR rates stratified by HCV RNA (<400,000 vs ≥400,000 IU/mL) in (A) HCV mono-infected participants adherent to therapy (n = 48; with genotype available) and (B) HCV/HIV co-infected participants adherent to therapy (n = 29; with genotype available). bl, baseline; vl, viral load.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

8. Supplementary Figure 3
Impact of estimated duration of infection (≤26 wk, 27–52 wk, and >52 wk) on SVR in HCV (n = 74) and HCV/HIV co-infected (n = 35) participants.
Gastroenterology  , e2DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions